Maternal Use of Anti-Obesity Drugs and Infant Congenital Malformations
Relatively little data are available on the use of modern anti-obesity drugs in early pregnancy. There seems to be no effect of the use of orlistat but an indicated doubling of malformation risk after sibutramine which should be avoided in early pregnancy.
- Heinonen OP, Sloan D, Shapiro S. Birth defects and drugs in pregnancy. Littleton, MA: Publishing Sciences Group, Inc.; 1977.Google Scholar